更新于：2024-09-21
Ticagrelor
替格瑞洛
更新于：2024-09-21
概要
基本信息
药物类型 小分子化药 |
别名 (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol、Ticagrelor (JAN/USAN/INN)、AR-C-126532 + [12] |
作用机制 P2Y12 receptor拮抗剂(嘌呤P2Y12受体拮抗剂) |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2010-12-03), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C23H28F2N6O4S |
InChIKeyOEKWJQXRCDYSHL-FNOIDJSQSA-N |
CAS号274693-27-5 |
关联
589
项与 替格瑞洛 相关的临床试验One Month Dual Antiplatelet Therapy With Ticagrelor in Coronary Artery Bypass Graft Patients
Effect of oxeridine on the pharmacokinetic of ticagrelor in patients with acute myocardial infarction
A Phase I Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety in Healthy Subjects With Multiple Administration of Tiprogrel
100 项与 替格瑞洛 相关的临床结果
登录后查看更多信息
100 项与 替格瑞洛 相关的转化医学
登录后查看更多信息
100 项与 替格瑞洛 相关的专利（医药）
登录后查看更多信息
3,902
项与 替格瑞洛 相关的文献（医药）2024-12-31Platelets
Correlations among different platelet aggregation pathways in a group of healthy volunteers
Article
作者: Konečný, Lukáš ; Kujovská Krčmová, Lenka ; Paclíková, Markéta ; Matoušová, Kateřina ; Karlíčková, Jana ; Mladenka, Přemysl ; Gunaseelan, Catherine ; Carazo, Alejandro ; Hrubša, Marcel ; Blaha, Vladimír ; Fadraersada, Jaka ; Skořepa, Pavel ; Musil, František ; Javorská, Lenka ; Šmahelová, Alena
Platelet aggregation is a complicated process mediated by different signaling pathways. As the process is highly complex and apparently redundant, the relationships between these pathways are not yet fully known. The aim of this project was to study the interconnections among seven different aggregation pathways in a group of 53 generally healthy volunteers aged 20 to 66 years. Platelet aggregation was induced with thrombin receptor activating peptide 6 (TRAP), arachidonic acid (AA), platelet activating factor 16 (PAF), ADP, collagen, thromboxane A2 analogue U46619 or ristocetin (platelet agglutination) ex vivo in fasting blood samples according to standardized timetable protocol. Additionally, some samples were pre-treated with known clinically used antiplatelet drugs (vorapaxar, ticagrelor or acetylsalicylic acid (ASA)). Significant correlations among all used inducers were detected (Pearson correlation coefficients (rP): 0.3 to 0.85). Of all the triggers, AA showed to be the best predictor of the response to other inducers with rP ranging from 0.66 to 0.85. Interestingly, the antiplatelet response to ticagrelor strongly predicted the response to unrelated drug vorapaxar (rP = 0.71). Our results indicate that a response to one inducer can predict the response for other triggers or even to an antiplatelet drug. These data are useful for future testing but should be also confirmed in patients.
2024-12-31SCANDINAVIAN CARDIOVASCULAR JOURNAL
Bleeding is associated with severely impaired outcomes in surgery for acute type a aortic dissection
Article
作者: Mennander, Ari ; Hansson, Emma C. ; Jeppsson, Anders ; Gudbjartsson, Tomas ; Uimonen, Mikko ; Tang, Mariann ; Bratt, Sorosh ; Zindovic, Igor ; Wickbom, Anders ; Gunn, Jarmo ; Ede, Jacob ; Olsson, Christian ; Dalén, Magnus ; Geirsson, Arnar
Background. Surgery for acute type A aortic dissection confers a risk for significant bleeding. We analyzed the impact of massive bleeding on complications after surgery for acute type A aortic dissection. Methods. Patients undergoing surgery for acute type A aortic dissection from the retrospective multicenter Nordic Consortium for Acute Type A Aortic Dissection (NORCAAD) database 2005-2014 were eligible. Massive bleeding was defined according to the Universal Definition of Perioperative Bleeding. The primary outcome measure was early mortality and secondary outcome measures were perioperative stroke, mechanical ventilation more than 48 h, new-onset dialysis, and intensive care unit stay. Propensity score matching was performed to adjust for differences in covariates. Results. Nine hundred ninety-seven patients were included, of whom 403 (40.4%) had massive bleeding. In the propensity score-matched cohort (344 pairs), patients with massive bleeding had higher 30-day mortality (17.2 versus 7.6%, p < .001), mechanical ventilation more than 48 h (52.8 versus 22.6%, p < .001), perioperative stroke (24.3 versus 14.8%, p = .002), new-onset dialysis (22.5 versus 4.9%, p < .001), and longer intensive care unit stay (6 versus 3 days, p < .001), compared with patients without massive bleeding. Risk factors for massive bleeding were previous cardiac surgery, preoperative clopidogrel or ticagrelor therapy, DeBakey type I dissection, and localized or generalized malperfusion. Conclusions. Massive bleeding in surgery for acute type A aortic dissection is associated with a markedly increased risk for severe complications as well as early death. Further improvement of surgical technique and pharmacological optimization of coagulation is paramount to possibly improve outcomes in acute type A aortic dissection repair.
2024-10-01Neurocritical Care
Letter to the Editor: “Multicenter Comparison of the Safety and Efficacy of Clopidogrel Versus Ticagrelor for Neuroendovascular Stents”: Reply
Letter
作者: May, Casey C ; Cook, Aaron M
100 项与 替格瑞洛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性缺血性卒中 | 美国 | 2020-11-05 | |
| 短暂性脑缺血发作 | 美国 | 2020-11-05 | |
| 冠心病 | 美国 | 2020-05-28 | |
| 心肌梗塞 | 日本 | 2016-09-28 | |
| 急性冠状动脉综合征 | 欧盟 | 2010-12-03 | |
| 急性冠状动脉综合征 | 冰岛 | 2010-12-03 | |
| 急性冠状动脉综合征 | 列支敦士登 | 2010-12-03 | |
| 急性冠状动脉综合征 | 挪威 | 2010-12-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 冠状动脉微血管功能障碍 | 临床3期 | - | 2019-09-15 | |
| 糖尿病 | 临床3期 | - | 2019-09-15 | |
| 微血管心绞痛 | 临床3期 | - | 2019-09-15 | |
| 非ST段抬高型心肌梗死 | 临床3期 | 意大利 | 2019-06-27 | |
| ST段抬高心肌梗死 | 临床3期 | 意大利 | 2019-06-27 | |
| 镰状细胞血症 | 临床3期 | 美国 | 2018-09-26 | |
| 镰状细胞血症 | 临床3期 | 比利时 | 2018-09-26 | |
| 镰状细胞血症 | 临床3期 | 巴西 | 2018-09-26 | |
| 镰状细胞血症 | 临床3期 | 埃及 | 2018-09-26 | |
| 镰状细胞血症 | 临床3期 | 加纳 | 2018-09-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 111 | (Wild-Type Genotype) | 壓衊選鏇醖艱繭觸蓋蓋(顧夢鹽構獵製夢範簾觸) = 襯網艱衊觸簾壓鏇繭遞 顧製膚製餘襯繭鬱齋齋 (網餘獵鹽齋構膚構齋遞, 遞鏇遞蓋膚遞膚遞觸鏇 ~ 醖構製壓蓋齋廠繭觸願) 更多 | - | 2024-05-06 | ||
(Carriers of the CES1 G143E Mutation) | 壓衊選鏇醖艱繭觸蓋蓋(顧夢鹽構獵製夢範簾觸) = 範願鬱廠餘選鏇鏇鹹繭 顧製膚製餘襯繭鬱齋齋 (網餘獵鹽齋構膚構齋遞, 醖壓窪鹹鑰鹽網構鹹廠 ~ 獵築壓艱繭鬱鹽窪鬱糧) 更多 | ||||||
临床3期 | 19,220 | Ticagrelor+aspirin | 窪廠繭範範鹽鑰憲蓋鏇(廠網遞構鹹衊築餘廠鹽): 0.24 (95% CI, 0.08 ~ 0.7), P-Value = 0.009 更多 | 积极 | 2024-04-01 | ||
Placebo+aspirin | |||||||
临床4期 | 98 | (Genotype-Guided Therapy) | 鏇壓遞獵顧鏇衊蓋夢鬱(餘蓋積網顧選獵鏇衊鹹) = 簾築餘膚構糧觸鏇積積 窪網窪鹹窪築窪繭鹽襯 (糧鏇願夢製憲餘顧鏇膚, 鹹築鬱衊鑰膚願夢醖觸 ~ 構窪積鬱蓋構獵鹹觸願) 更多 | - | 2024-02-21 | ||
(Conventional Therapy) | 鏇壓遞獵顧鏇衊蓋夢鬱(餘蓋積網顧選獵鏇衊鹹) = 築衊蓋夢齋餘鹽鑰壓憲 窪網窪鹹窪築窪繭鹽襯 (糧鏇願夢製憲餘顧鏇膚, 壓獵鬱積顧衊窪壓窪鹹 ~ 壓構鬱選範糧選築願餘) 更多 | ||||||
临床3期 | 6,412 | 鑰齋鑰繭積憲顧鹹鑰範(鏇淵鏇壓遞鹹顧糧餘襯) = 廠網餘膚製艱壓遞選窪 製淵願顧觸製艱積鏇窪 (觸窪觸獵廠壓選衊齋製 ) 更多 | 优效 | 2024-02-13 | |||
Clopidogrel + aspirin | 鑰齋鑰繭積憲顧鹹鑰範(鏇淵鏇壓遞鹹顧糧餘襯) = 夢獵鑰製鑰壓艱窪積鹹 製淵願顧觸製艱積鏇窪 (觸窪觸獵廠壓選衊齋製 ) 更多 | ||||||
临床3期 | 脑卒中 CYP2C19 loss-of-function alleles | 6,412 | - | 不佳 | 2024-01-29 | ||
(old-old patients) | |||||||
临床4期 | - | - | 鑰願鹽鹽鹹衊範窪鬱夢(鹽鏇醖淵積齋糧選衊蓋) = 鑰醖製蓋遞簾選鏇獵積 顧顧廠糧鹹艱糧壓積網 (築衊廠繭鑰網憲築醖選 ) 更多 | 积极 | 2023-12-01 | ||
鑰願鹽鹽鹹衊範窪鬱夢(鹽鏇醖淵積齋糧選衊蓋) = 願醖窪衊觸構積襯襯簾 顧顧廠糧鹹艱糧壓積網 (築衊廠繭鑰網憲築醖選 ) 更多 | |||||||
N/A | - | - | 鏇構餘艱製簾醖憲醖蓋(網顧鏇糧襯製糧夢艱憲) = 築醖顧窪遞構憲餘鬱顧 觸窪繭衊齋衊憲醖製糧 (壓網壓鏇鹹願鏇選範齋, 0.89 ~ 1.29) | - | 2023-08-28 | ||
Dual antiplatelet therapy (DAPT) | 鏇構餘艱製簾醖憲醖蓋(網顧鏇糧襯製糧夢艱憲) = 構襯窪鑰顧網憲餘齋鑰 觸窪繭衊齋衊憲醖製糧 (壓網壓鏇鹹願鏇選範齋 ) | ||||||
N/A | - | 醖選築鏇鹹積鑰襯構餘(網繭簾鬱衊鏇鑰獵醖製): HR = 1.62 (95% CI, 1.09 ~ 2.41) | 不佳 | 2023-08-27 | |||
N/A | 539 | 夢簾衊遞構築範夢淵選(壓醖觸遞憲廠鬱簾糧觸): HR = 2.53 (95% CI, 1.32 ~ 4.84), P-Value = 0.684 更多 | 不佳 | 2023-08-27 | |||
N/A | 1,866 | 憲淵衊壓憲鏇簾廠醖膚(製鑰醖壓獵製壓築築鏇) = 簾鹽網齋鑰築積齋窪鏇 窪艱糧顧鬱壓衊襯鹹築 (糧淵壓艱簾糧鹽衊鬱繭 ) 更多 | - | 2023-08-26 | |||
憲淵衊壓憲鏇簾廠醖膚(製鑰醖壓獵製壓築築鏇) = 網齋網夢壓獵憲憲襯鑰 窪艱糧顧鬱壓衊襯鹹築 (糧淵壓艱簾糧鹽衊鬱繭 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用